Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11
Authors' conclusion
Based on a willingness-to-pay threshold of GBP 20 000 per QALY gained, once-weekly semaglutide 1 mg was projected to be highly cost-effective versus insulin aspart for the treatment of type 2 diabetes in the UK.
Study context
- Population
- Modelled cohort with T2D in the UK, baseline characteristics from SUSTAIN 11
- Comparison
- Once-weekly semaglutide 1 mg vs insulin aspart
- Outcome
- Incremental cost-effectiveness ratio (cost per QALY gained)
- Follow-up
- Patients' lifetimes
Methodological detailslong-term, IQVIA CORE Diabetes Model (vers 9.0), based on SUSTAIN 11, UK healthcare payer perspective, lifetime horizon
- Long-term
- IQVIA CORE Diabetes Model (vers 9.0)
- Based on SUSTAIN 11
- UK healthcare payer perspective
- Lifetime horizon
Main finding
As reported in the abstract
Cost-effectiveness · lifetime
ICER
4457 GBP per QALY gained
Cost-effectiveness
Quality-adjusted life expectancy gain
0.18 QALYs
Cost-effectiveness
Direct cost difference
800 GBP
higher with semaglutide
Further findings
- Reduced incidence and delayed time to onset of diabetes-related complications with semaglutide
Original publication
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11. Diabetes Obes Metab. Published 2 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →